Impact of obstructive sleep apnea on cognitive performance

Felipe Cunha Bawden¹, Cristiane Assis Oliveira², Paulo Caramelli¹,³

ABSTRACT
Objective: To evaluate the impact of obstructive sleep apnea (OSA) on cognition.
Method: We compared the performance of 17 patients with polysomnographic diagnosis of OSA in brief cognitive tests to that of 20 healthy controls, matched for age and education. The testing battery included the Mini-Mental State Examination (MMSE), Brief Cognitive Screening Battery (BCSB), Digit-Symbol (DS) and Phonemic Verbal Fluency (FAS). Anthropometric measures and scores from the Epworth Sleepiness Scale were also recorded. Results: OSA patients performed significantly worse than controls in the MMSE, in memory items from the BCSB, in DS and also in FAS. OSA patients also exhibited higher body mass index, increased neck circumference and higher scores in Epworth Sleepiness Scale than controls.
Conclusion: OSA significantly impairs cognitive performance, especially within the domains of attention, memory and executive functioning. These deficits may be detected by brief and easy-to-administer cognitive tests.
Key words: sleep disorders, obstructive sleep apnea, excessive daytime sleepiness, cognitive performance.

Obstructive sleep apnea (OSA) is a disorder associated with episodic sleep disruptions in airway patency, followed by reduction of oxygen saturation and arousals throughout the night. In result of the chronic deprivation of sleep which it determines, OSA can lead to impairment of productivity at work, traffic accidents and also to endocrine and cardiovascular diseases⁴⁻⁵.

The prevalence of OSA is estimated to range from 2% to 4% of the population aged 30 to 60 years, according to the first major US population-based study con-
ducted in 1993\textsuperscript{6-8}. Risk factors include advanced age, male gender, obesity and craniofacial morphology\textsuperscript{6-8}. The nightly use of positive pressure in the upper airway provided by Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP) is the most effective treatment of OSA. Weight loss, abstinence from alcohol and sedatives, to prevent supine sleeping and nasal steroids in patients with concurrent rhinitis constitute behavioral measures which are potentially beneficial for all cases of OSA\textsuperscript{6,8}. Oral appliance therapy is also a treatment option for patients with mild to moderate disease, as well as for those patients with severe disease who are unable to tolerate CPAP therapy\textsuperscript{9,10}. Upper-airway surgery can be an alternative treatment in selected cases, but its role remains unclear. There is no current effective drug treatment for OSA, although modafinil can be used as adjuvant to reduce the symptoms of residual daytime sleepiness despite the adequate CPAP use\textsuperscript{6,9}.

There is still no consensus on the mechanisms by which OSA affects cognitive performance. Excessive daytime sleepiness (EDS) is the most common symptom observed during wakefulness in these patients, which may have induced the initial studies to consider cognitive impairment as being entirely secondary to EDS. More recent investigations, however, have shown that neuronal damage determined by intermittent hypoxia may affect performance on neuropsychological tests\textsuperscript{11}. This theory has been recently supported by a study using functional neuroimaging associated with neuropsychological testing in patients with OSA\textsuperscript{12}.

In the present study we aimed to investigate the effects of OSA on the performance in brief cognitive tests assessing attention and executive functions, comparing the performance of patients with polysomnographic diagnosis of OSA with healthy controls.

**METHOD**

Patients consecutively submitted to polysomnography between October 2009 and January 2010 in the sleep laboratory of the Hospital Belo Horizonte, in Belo Horizonte MG, Brazil, who were suspected to have OSA were invited to participate in the study. Exclusion criteria included ages out of the range of 18 to 59 years, illiteracy or marked visual impairment. Shortly before implantation of electrodes, while in the waiting rooms, patients were evaluated. The study protocol initially included the measurement of anthropometric data (weight, height and neck circumference). Then, patients were submitted to four brief cognitive tests, a self-administered questionnaire of sleepiness (Epworth Sleepiness Scale) and polysomnography.

A group of healthy individuals without evidence of EDS (demonstrated by a score <9 on the Epworth Sleepiness Scale) were recruited in the community to constitute a control group. These individuals underwent the same procedures described for the OSA group, except for polysomnography. The same exclusion criteria adopted for patients were employed for controls.

The study was approved by the Ethics Committee in Research of the Federal University of Minas Gerais and all participants signed an informed consent before the evaluation.

**Cognitive tests**

**Digit-Symbol Test (DST)** – DST is part of the Wechsler Adult Intelligence Scale (WAIS) and provides a measure of psychomotor performance, motor persistence, sustained attention, response speed and visuospatial coordination, with results accepted as independent of intelligence\textsuperscript{13}. It consists on nine digit-symbol pairs followed by a list of digits. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time (120 sec) is measured.

**Mini-Mental State Examination (MMSE)** – The MMSE is a worldwide used screening tool for global cognitive assessment\textsuperscript{13-15}. The test investigates temporal and spatial orientation, memory (immediate and delayed recall), attention, calculation skills, language and constructive praxis. The score ranges from 0 to 30 points, with higher scores corresponding to better performance.

**Brief Cognitive Screening Battery (BCSB)** – It consists of three presentations of 10 figures drawn on a sheet of paper, with assessment of incidental memory, immediate memory and learning, a delayed recall after a brief interference represented by category fluency (animals per minute) and clock drawing tests, and recognition. Thus, the BCSB provides five measures related to memory (incidental, immediate, learning, delayed recall and recognition), language, semantic memory and executive functions\textsuperscript{16}.

**Phonemic Verbal Fluency (FAS)** – This test assesses verbal fluency for the production of words beginning with letters “F”, “A” and “S” (one minute for each letter).

**Epworth Sleepiness Scale (ESS)**

The ESS is a self-administered questionnaire and refers to the possibility of falling asleep in eight different situations of everyday life\textsuperscript{17,18}. The likelihood of napping is quantified with a scale ranging from 0 (zero) to 3 (three), where 0 corresponds to none and three, the most likely to doze. Scores greater than 10 suggest a high possibility of EDS. Scores over 16 are indicative of severe sleepiness, more commonly found in patients with moderate or severe OSA, narcolepsy, or idiopathic hypersomnia\textsuperscript{18}. 

---

**References**

\textsuperscript{1} Bawden et al. Obstructive sleep apnea: cognitive performance. Arq Neuropsiquiatr 2011;69(4)
Polysomnography
Polysomnography is the procedure dedicated to monitor multiple physiological parameters during sleep\textsuperscript{6,19,20}. The measurements included in this study were sleep electroencephalography, electrooculography, chin and leg electromyography, electrocardiography, and recordings of airflow (thermistor and nasal pressure monitor), respiratory effort (strain gauges), oxygen saturation, body position and snore microphone. A technician was in constant attendance. OSA was classified as mild (5 to 15 respiratory events per hour), moderate (as greater than 15 to 30 events per hour) and severe (as greater than 30 events per hour)\textsuperscript{20}.

Statistical analysis
For all statistical tests we adopted the significance level of 5%. Data were initially tested through Kolmogorov-Smirnov test to determine whether distribution was normal or not. To verify the relationship between numerical variables with normal distribution test we used the Pearson correlation test, while the Spearman rank correlation test was applied to non-parametric variables. To check the proportion in each level of categorical variables we used Chi-Square Pearson. SPSS 18.0 was used to perform data analysis. To investigate the existence of differences between cognitive performance of OSA patients and controls we used statistical tests for independent samples. The tests used were Student’s t test for variables with normal distribution and Wilcoxon test otherwise.

RESULTS
The average time for administration of the cognitive tests and the ESS was 30 minutes. During the recruitment period 26 patients were submitted to cognitive testing and underwent polysomnography in the clinic. Of these, 17 were diagnosed with OSA, being still untreated, and were selected for the study. Among the remaining cases, two had OSA under CPAP treatment, four had primary snoring and two cases had inconclusive results, and were thus excluded from the analysis.

Among the study patients, eight (47.1%) were diagnosed with severe OSA, five (29.4%) with moderate OSA and four (23.5%) with mild OSA.

For the control group, 20 healthy individuals adequately matched for age, gender and education with the OSA patients were evaluated. Table 1 displays the main sociodemographic and anthropometric characteristics of patients and controls.

MMSE scores were higher among controls than among OSA patients. In DST, the performance of OSA patients and controls were similar with respect to hits, but the former group had significantly lower scores in the total number of cells satisfied, but committed fewer errors. In the BCSB, controls performed significantly better than OSA patients in incidental memory, immediate memory, learning and delayed recall. No significant differences emerged between the two groups on category fluency and clock drawing. In FAS, controls produced a significantly higher number of words beginning with letters A and S, accounting for a higher total score in the test. Table 2 shows the results of OSA patients and controls in the cognitive tests.

DISCUSSION
In the present study, which did not use sophisticated methods of investigation, we found that performance of OSA patients was impaired in comparison to healthy controls in tests assessing attention, graphomotor speed, memory, language and executive functions. Hence, a variety of cognitive domains seems to be affected in this condition and brief cognitive testing may detect such changes.

In DST, OSA patients were slower than controls, although presenting fewer errors. The small sample size may be responsible for this unexpected finding and needs further exploration. As for episodic memory, the performance of the OSA group in the BCSB was also impaired in relation to controls in four different measures, namely, incidental memory, immediate memory, learning and recall. Finally, in the FAS test patients produced fewer words that their counterparts.

Table 1. Main sociodemographic and anthropometric characteristics of OSA patients and controls.

<table>
<thead>
<tr>
<th></th>
<th>OSA</th>
<th>Controls</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>41.4±13.0</td>
<td>27.6±8.7</td>
<td>0.74</td>
</tr>
<tr>
<td>Educational level (years)</td>
<td>11.5±3.8</td>
<td>13.3±3.8</td>
<td>0.18</td>
</tr>
<tr>
<td>BMI</td>
<td>30.4±7.0</td>
<td>23.2±1.8</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Neck circumference (centimeters)</td>
<td>41.9±4.2</td>
<td>35.5±2.2</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>ESS</td>
<td>12.2±5.2</td>
<td>5.1±2.1</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

OSA: Obstructive Sleep Apnea; BMI: Body Mass Index; ESS: Epworth Sleepiness Scale. Data represent mean±standard deviation.
The impact of OSA on cognitive performance may provide additional parameters to monitor clinical improvement after therapeutic interventions. Attention, episodic memory and executive function tests rank among the tools which may be useful in this context. Moreover, the MMSE, a brief and global measure of cognitive functioning, may also depict some changes in these patients, although scores obtained in the OSA group were within the normal limits for the Brazilian population.

Previous studies investigating cognitive performance in patients with OSA have been able to distinguish the impairment resulting from EDS from that determined by chronic obstructive pulmonary disease, which traditionally assumes the occurrence of ischemic prefrontal lesions.

Yaouhi and colleagues submitted 16 patients with OSA to neuropsychological testing and functional neuroimaging. Although the authors did observe only little deficits in the functions assessed (mainly memory and motor function), functional brain changes could be detected, suggesting that such modifications precede the clinical manifestations.

One study conducted in Finland with 40 newly diagnosed OSA cases and 20 healthy controls also found impaired performance of the former in some neuropsychological tests, such as the copy of the Rey figure, Block Design and Trail Making B. In a subsequent study, this same group of investigators demonstrated that even prolonged CPAP treatment was not able to match the performance of both groups, especially in learning tasks.

We believe that the demonstration of cognitive impairment, even being of mild severity, is enough to motivate further studies aiming at elucidating the etiology of these deficits. Despite that researchers still fail to reach a consensus on the issue EDS versus neuronal damage, the mere possibility of irreversible brain damage associated with a highly prevalent and often underestimated medical problem is an alarming feature. The latest observations on neuronal death associated with intermittent hypoxia in animal models of OSA and functional neuroimaging studies in humans help to understand the nature of injuries, leading to speculation about strategies to halt or even to reverse this process. A better understanding of the mechanisms of neuronal dysfunction or cell death that may occur in OSA might bring benefits to these patients.

Screening methods for OSA should be inexpensive. ESS, available in a validated version in Portuguese for use in Brazil is an appropriate use for this purpose and has an excellent cost-benefit profile as well as being easy and quick to administer. The limitations related to the subjectivity of the answers provided to questions from the ESS can only be overcome at the moment with the use of objective tests to measure sleepiness, as the multiple sleep latency test, the gold standard for this diagnosis. However, this procedure is not effective in the context of screening because of its high cost and difficulty of large-scale application. The infrastructure required for the test is better used if dedicated to diagnostic confirmation through polysomnography performed in individuals identified with EDS in the ESS.

With respect specifically to OSA, screening in the

<table>
<thead>
<tr>
<th>Cognitive test</th>
<th>OSA</th>
<th>Controls</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMSE</td>
<td>28.0±1.3</td>
<td>29.1±0.9</td>
<td>0.01</td>
</tr>
<tr>
<td>DST (Total)</td>
<td>42.1±14.8</td>
<td>52.2±13.3</td>
<td>0.04</td>
</tr>
<tr>
<td>DST (Errors)</td>
<td>0.3±1.5</td>
<td>0.9±1.2</td>
<td>0.05</td>
</tr>
<tr>
<td>DST (Hits)</td>
<td>41.9±15.4</td>
<td>51.2±13.0</td>
<td>0.04</td>
</tr>
<tr>
<td>BCSB incidental recall</td>
<td>5.4±1.5</td>
<td>7.4±1.0</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>BCSB immediate recall</td>
<td>7.9±1.3</td>
<td>8.7±1.0</td>
<td>0.02</td>
</tr>
<tr>
<td>BCSB learning</td>
<td>8.8±1.0</td>
<td>9.6±0.7</td>
<td>0.01</td>
</tr>
<tr>
<td>BCSB delayed recall</td>
<td>8.2±1.6</td>
<td>9.1±1.0</td>
<td>0.02</td>
</tr>
<tr>
<td>Category fluency (animals)</td>
<td>17.8±5.3</td>
<td>20.0±4.3</td>
<td>0.18</td>
</tr>
<tr>
<td>Clock drawing</td>
<td>8.9±1.7</td>
<td>9.4±0.5</td>
<td>0.26</td>
</tr>
<tr>
<td>FAS - F</td>
<td>15.3±4.3</td>
<td>15.8±2.9</td>
<td>0.68</td>
</tr>
<tr>
<td>FAS - A</td>
<td>12.5±3.4</td>
<td>15.6±2.9</td>
<td>0.01</td>
</tr>
<tr>
<td>FAS - S</td>
<td>13.0±3.9</td>
<td>15.6±2.8</td>
<td>0.02</td>
</tr>
<tr>
<td>FAS Total</td>
<td>40.8±10.4</td>
<td>47.0±6.6</td>
<td>0.03</td>
</tr>
</tbody>
</table>

OSA: Obstructive Sleep Apnea; MMSE: Mini-Mental State Examination; DST: Digit-Symbol Test; BCSB: Brief Cognitive Screening Battery; FAS: Phonemic Verbal Fluency (letters F-A-S). Data represent mean±standard deviation.
outpatient setting is a simple task that requires a brief clinical history and the assessment of good clinical predictors, such as ESS score, neck circumference and BMI.\textsuperscript{6,10} Moreover, the use of standardized cognitive tests in the context of Sleep Medicine, in addition to the other above-mentioned measures, could contribute to a more accurate assessment of OSA, since it would offer objective information on the clinical consequences of the syndrome.

In conclusion, we found that OSA was responsible for deficits in attention, memory and executive functioning. Objectively, OSA patients presented signs of reduced information processing speed, a decrease in learning and delayed recall and also an impairment in phonemic verbal fluency. These findings are in line with the international literature on the subject. However, the limitations of the present study did not permit speculation about the etiology of these cognitive deficits.

REFERENCES